Inhibition of EGFR with erlotinib attenuated the development of diabetic nephropathy in type 1 diabetes, which was mediated at least in part by inhibition of mTOR and activation of AMPK, with increased autophagy and inhibition of ER stress. This evidence concerns the gene EGFR and type 1 diabetes mellitus.